Premium
The need for new and better antidepressants: reboxetine a new option
Author(s) -
Dencker Sven J.
Publication year - 2000
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1034/j.1600-0447.2000.02602.x
Subject(s) - reboxetine , fluoxetine , tricyclic , reuptake inhibitor , antidepressant , neurotransmitter systems , reuptake , desipramine , neurotransmitter , pharmacology , psychology , serotonin , medicine , psychiatry , neuroscience , dopamine , central nervous system , anxiety , receptor
The selective serotonin reuptake inhibitors (SSRIs) have obtained global attention but have not demonstrated superior efficacy in major depression compared with older tricyclic antidepressants. From a pharmacological viewpoint the noradrenergic system in the brain appears to have a central role in neurotransmitter organization. The importance of noradrenaline in depression is supported by its association with clinical parameters such as vigilance and drive. Reboxetine is a selective noradrenaline reuptake inhibitor — the first in its class to be marketed. In both preclinical and clinical studies reboxetine has been found to be an effective and safe antidepressant. Furthermore, reboxetine restores a patients' social functioning, producing a better quality of remission than fluoxetine.